Neurocrine Biosciences Inc (NBIX : NASDAQ)
Common Stock
$164.63
USD
+4.87 (3.05%)
Last updated: 2026-11-06
Follow NBIX
NBIX
Neurocrine Biosciences Inc
WealthAwesomePerformance
1 Day
+3.05%
1 Week
+12.68%
1 Month
+14.75%
YTD
+3.54%
Key Statistics
Market Cap
$16.66B
52W High
$186.12
52W Low
$122.14
P/E Ratio
24.43
50 Day MA
$147.22
200 Day MA
$148.02
Beta
0.33
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/6/2026 | $159.98 | $165.86 | $158.66 | $164.63 | $164.63 | 1,507,500 |
| 11/5/2026 | $167.68 | $167.68 | $159.50 | $159.76 | $159.76 | 1,482,476 |
| 11/4/2026 | $166.36 | $169.01 | $162.02 | $166.05 | $166.05 | 2,220,210 |
| 11/3/2026 | $159.00 | $169.53 | $157.91 | $164.85 | $164.85 | 4,052,709 |
| 11/2/2026 | $145.70 | $147.57 | $143.75 | $145.35 | $145.35 | 1,968,494 |
| 10/30/2026 | $147.13 | $149.25 | $145.22 | $146.10 | $146.10 | 1,322,300 |
| 10/29/2026 | $146.57 | $147.17 | $145.37 | $146.38 | $146.38 | 830,686 |
| 10/28/2026 | $144.56 | $145.98 | $143.00 | $145.53 | $145.53 | 1,091,437 |
| 10/27/2026 | $145.01 | $146.59 | $143.91 | $146.00 | $146.00 | 1,122,272 |
| 10/26/2026 | $143.99 | $146.00 | $142.34 | $145.87 | $145.87 | 1,283,832 |
Analyst Price Targets
Based on 29 analysts covering NBIX · as of Nov 9, 2026
Wall Street analysts forecast NBIX stock price to rise 26.4% over the next 12 months.
Consensus
Strong Buy4.59 / 5.00
Avg. Target
US$208.11
+26.4% Upside
Previously US$207.50 on Nov 5, 2026
Current Price
US$164.63
Last close
Analyst Breakdown (29 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on NBIX's historical volatility
30-Day Vol
45.5%
Annualized
90-Day Vol
39.1%
Annualized
Trend (90d)
+36.8%
Annualized drift
90d Mean
US$187.75
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$172.00 | US$147.02 – US$201.23 |
| 60 trading days | US$179.70 | US$143.94 – US$224.36 |
| 90 trading days | US$187.75 | US$143.07 – US$246.39 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Financials
- Revenue (TTM)
- $3.70B
- EBITDA
- $1.07B
- Profit Margin
- 18.98%
- ROE (TTM)
- 20.42%
- EPS (Diluted)
- 6.74
- Book Value
- 38.29
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About NBIX.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| ALPS | Alps Group Inc | $1.65 | +424.50% |
| SDA | SunCar Technology Group Inc. | $0.38 | +145.12% |
| STAK | STAK Inc. Ordinary Shares | $3.26 | +82.12% |
| NEXR | Nexera Technologies Ltd. | $2.10 | +75.73% |
| GOGO | Gogo Inc | $3.88 | +71.52% |
| CDT | CDT Equity Inc. | $1.31 | +55.95% |
| CIIT | Tianci International, Inc. Common Stock | $2.40 | +54.84% |
| VSA | VisionSys AI Inc. | $2.35 | +52.60% |
NBIX.US news timeline
1 article covering NBIX.US, most recent first
Latest